News
INM
0.7000
-1.74%
-0.0124
Weekly Report: what happened at INM last week (0406-0410)?
Weekly Report · 4d ago
Weekly Report: what happened at INM last week (0330-0403)?
Weekly Report · 04/06 09:32
InMed Pharmaceuticals Announces ATM Offering Prospectus Filing
TipRanks · 04/03 21:00
InMed Pharmaceuticals files prospectus supplement for at-the-market common share offering
Reuters · 04/03 20:20
InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance
TipRanks · 03/30 22:58
InMed receives Nasdaq notification regarding minimum bid price compliance
TipRanks · 03/30 15:22
Weekly Report: what happened at INM last week (0323-0327)?
Weekly Report · 03/30 09:32
InMed warned by Nasdaq over minimum bid price non-compliance
TipRanks · 03/27 22:50
InMed Pharma gets Nasdaq non-compliance notice
Seeking Alpha · 03/27 21:12
InMed Pharmaceuticals drops on Nasdaq notice; bid price stays below $1.00 for 30 straight sessions
Reuters · 03/27 21:05
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Newsfile · 03/27 21:05
InMed Reports Positive Preclinical Data for Alzheimer’s Candidate
TipRanks · 03/23 11:58
InMed Pharmaceuticals announces preclinical data on effects of INM-901
TipRanks · 03/23 11:50
InMed Reports Preclinical Data Showing Reduced Brain Inflammation in Alzheimer's Models
Benzinga · 03/23 11:41
INMED PHARMACEUTICALS INC - PLANS PRE-IND MEETING WITH U.S. FDA FOR INM-901 IN Q3 2026 - SEC FILING
Reuters · 03/23 11:34
InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models
Reuters · 03/23 11:32
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Newsfile · 03/23 11:30
Weekly Report: what happened at INM last week (0316-0320)?
Weekly Report · 03/23 09:30
InMed Pharmaceuticals Files Prospectus To Offer Up To $50M In Securities
Benzinga · 03/20 21:12
InMed Pharmaceuticals files $50M mixed securities shelf
TipRanks · 03/20 21:05
More
Webull provides a variety of real-time INM stock news. You can receive the latest news about Inmed Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About INM
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.